Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Medical World News

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

Asthma

Atopic Dermatitis

Biosimilars

Breast Cancer

COPD

COVID-19

Cholangiocarcinoma

Chronic Kidney Disease

Colorectal Cancer

Dermatology

Diabetes

Digital Health

Employers

Epilepsy

Heart Failure

Hematology

Hemophilia

Immuno-Oncology

Infectious Disease

Inflammation

Leukemia and Lymphoma

Liver

Lung Cancer

Lupus

Major Depressive Disorder

Medicare

Multiple Myeloma

Myasthenia Gravis

Myelodysplastic Syndromes

Oncology

Ophthalmology

Parkinson Disease

Prostate Cancer

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Rare Disease

Reimbursement

Respiratory

Rheumatology

Skin Cancer

Sleep

Spinal Muscular Atrophy

Type 1 Diabetes

Vaccines

Women's Health

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

eNewsletter

Jaime is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an assistant editor.

She has a BA in print journalism from Penn State University. You can connect with Jaime on 

Articles

Having models like these that produce more plausible results are crucial for decision-making in an era of targeted treatments that often come with immature data, argued researchers of their findings for minimal residual disease (MRD) in newly diagnosed multiple myeloma (NDMM).


Including MRD Status Reduces Uncertainty in Long-term Survival Models of NDMM

Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.

He has an MA from University of Sioux Falls. You can connect with Jared on 

The bill could have saved CMS about $26.5 billion had it been in place from 2018-2020, the study showed. 

Inflation Reduction Act Could Cut Medicare Drug Spending by 5%, Study Suggests

Matthew is an associate editor for The American Journal of Managed Care® (AJMC®). He joined AJMC® in 2019 and creates content for 

, a 24-hour online program developed MJH Life Sciences® focusing on pressing topics within managed care, as well as the nonwork-related activities of health care stakeholders.

He has a BA in journalism & media studies and economics from Rutgers University. You can connect with Matthew on 

Approximately 70% of veterans with drug-resistant epilepsy reported diagnosis of at least 1 psychiatric condition, with female patients showing a higher prevalence than male patients.

Veterans With Drug-Resistant Epilepsy Show High Prevalence of Psychiatric Burden

Rose is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an editor.

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

The approval is based on results from the phase 3 TROPiCS-02 trial demonstrating overall and progression survival benefits with sacituzumab govitecan compared with physician’s choice of single-agent chemotherapy.

FDA Approves Sacituzumab Govitecan for Pre-Treated HR+/HER2- Metastatic Breast Cancer

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About Us

Contact

Editorial Staff

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

About AJMC

AJMC Journals

Anniversary

Author Forms

Authors

Nominate a Rising Leader

Institute for Value-Based Medicine

All Coverage

Event Coverage

Stakeholders

Academia

Health System

Payers

Providers

Topics

Webinars

1rem

) Oncology Value Coalition will be hosting a complimentary webinar on April 18, 2022, with experts from The US Oncology Network discussing the future of value-based cancer care.

Despite many successes, the Oncology Care Model (OCM) is set to expire in July 2022 with no replacement on the horizon. That doesn't mean the lessons of the OCM will be forgotten, but continuing the quality care efforts will be difficult. How will practices continue team-based care, patient navigation, and other enhanced services?




What are the successes of the OCM and how will its best practices be retained?

How have commercial payers responded to the movement toward value-based cancer care?

What is the role of the employer in promoting value-based cancer care?

What are the challenges practices face in meeting requirements from multiple stakeholders in the post-OCM era?

What enhanced services are at risk, and what can be done to protect patients?


Senior Director of Payer Solutions
The US Oncology Network


Vice President of Government Relations and Public Policy
McKesson Specialty Provider Organization, Supporting The US Oncology Network


Senior Director of Strategic Programs
The US Oncology Network


Vice President of Payer Relations and Practice Transformation
The US Oncology Network

Beyond the OCM: How Are Commercial Payers & Employers Delivering Value-Based Cancer Care?

In this webinar, participants will hear from top experts who will discuss the current state of mental health care, including the growing consensus on the need for change, strategies to provide high value care, and opportunities for collaboration among payers and other healthcare stakeholders.


Register now for this complimentary event

Highlight common challenges for employers and payers regarding coverage for mental health care

Discuss common definitions of value for payers, employers, and people with lived experience

Share strategies to incentivize high-value interventions for mental health care

Identify opportunities for future collaboration


President and CEO
National Alliance of Healthcare Purchaser Coalitions


Executive Director
Innovation and Value Initiative (IVI)


Vice President and Associate Medical Director
HealthPartners

AJMC Matters in Managed Care Webinar: Developing Strategies to Drive Value in Mental Health Care

In this webinar, participants will hear about current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries.



Medical Director
Intermountain Healthcare


Government Program Sales Director
SelectHealth


General Manager, Officer
SCAN Health Plan

AJMC Matters in Managed Care Webinar: Optimizing the Payer/Provider Relationship for a Successful Annual Enrollment Period

This webcast will be held 3 times on October 26, 2021, at 12 PM, 3 PM and 6 PM ET. To register, please complete the registration form on this page, and select the appropriate event on the following page. You will receive a confirmation email including a link to access the broadcast up to 10 minutes prior to the event start time.



Discuss the multiple myeloma treatment landscape complexity and its impacts on economic burden of disease and patient care.

Discuss the dispensing of oncology medications for multiple myeloma and best practices to ensure timely dispensing.

Explore evolving treatment options in multiple myeloma and how these may be impact stakeholders (practitioners, patients, and payers).


Vice President of Clinical Affairs and Chief Medical Officer
Cardinal Health Specialty Solutions

Bruce A. Feinberg, DO serves as vice president of Clinical Affairs and chief medical officer for Cardinal Health Specialty Solutions. He works across the specialty solutions businesses, consulting with payers, providers, pharma, patients, and policymakers. Since joining Cardinal Health, Dr. Feinberg has made more than 70 peer-reviewed contributions to value-based healthcare literature. In 2015, Dr. Feinberg was honored as a PharmaVoice 100 most inspirational life-science leader.


Director of Pharmaceutical Services
Emory Healthcare and Winship Cancer Institute

Ryan Haumschild PharmD, MS, MBA is an experienced director of pharmacy at Emory Healthcare and Winship Cancer Institute overseeing profit and loss responsibility, pharmacy operations, clinical services, formulary management, payer and health plan contracting, and medication use across one of the nation’s largest academic integrated delivery networks and Georgia’s only National Cancer Institute-designated Comprehensive Cancer Center. Dr. Haumschild provides strategic direction within oncology and non-oncology disease states, infusion and specialty pharmacy services, and the expansion of clinical services through treatment pathway development. He currently serves as an editorial board member at

e®, board member for both the Institute of Safe Medication Practices (ISMP) and Center for Biosimilars®, and was recently recognized as 40 under 40 by 3 separate organizations: University of Florida, 

, and Association for Value-Based Cancer Care.


Professor, Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute (TGen), City of Hope Cancer Center

Joseph Mikhael, MD, MEd, FRCPC, FACP, is a professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the chief medical officer of the International Myeloma Foundation (IMF).

Dr. Mikhael is a consultant hematologist and director of Myeloma Research at the HonorHealth Research Institute where he conducts phase 1 clinical trials. He also serves as a Councilor on the Executive of the American Society of Hematology. Dr. Mikhael is the chair of the Diversity, Equity and Inclusion Council for TGen.

Dr. Mikhael was recently a hematologist at Mayo Clinic Arizona where he served as a professor at the Mayo College of Medicine, associate dean of Graduate Medical Education and Deputy Director - Education at the Mayo Clinic Cancer Center. He has been recognized with numerous awards in education including being in the Mayo Clinic Resident and Fellow Association Hall of Fame as Educator of the Year. He was also recently named in the Top 100 Doctors in the United States.

Dr. Mikhael did his initial medical school training in Ottawa, Canada, followed by his hematology residency at Princess Margaret Hospital (PMH) in Toronto. He then did a multiple myeloma fellowship there along with a Masters’ Degree in Education from the University of Toronto. He was on staff at PMH until being recruited to Mayo Clinic in 2008.

He specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis and Waldenstrom’s macroglobulinemia. Dr. Mikhael is currently the principal investigator of many clinical trials, primarily in multiple myeloma. His other clinical research interests also include pharmaco-economics, communication skills and media relations. He has published over 150 peer reviewed articles in these fields. He lectures internationally on a regular basis. He is an active member of the International Myeloma Working Group and led the first ever American Society of Clinical Oncology Guidelines for Multiple Myeloma.

Dr. Mikhael leads the diversity efforts of the IMF, known as the M-Power program, seeking to empower patients and communities change the course of myeloma in at risk populations. He is also leading the IMF African American initiative whose goal is to improve the outcomes and care delivered to African Americans with myeloma – a disease with double the incidence in African Americans than Caucasians. Dr. Mikhael also spends about 20% of his time in the third world seeking ways to enhance research, collaboration and access to myeloma therapies in underprivileged countries.


Director of Pharmaceutical Services
Regional Cancer Care Associates, LLC

Tom Ollis, MS, RPh, is the director of Pharmacy for Regional Cancer Care Associates where he is responsible for ensuring that all patients receive the highest quality pharmaceutical care regarding both oral and intravenous therapies. Tom has extensive experience in clinical pharmacy practice including positions as an oncology pharmacist, medication safety officer, and chair of Institutional Review Board. Tom also has many years of management experience, including Director of Pharmacy positions at academic teaching hospitals. He has a Bachelor's Degree in Pharmacy from St. John’s University in New York, and a Master's Degree in Administration from Fairleigh Dickinson University in New Jersey.

The Impact of Evolving Treatment Options in Multiple Myeloma

Define actions and practices that constitute wasted and harmful care, as well as modalities that can replace these care routines

Describe how to rapidly translate high-quality evidence-based medicine (EBM) into daily practice in a variety of practice settings

Recognize how to leverage technology to utilize clinical algorithms, shared decision-making, and patient-reported outcomes to drive care decisions

Define how the use of analytics to measure healthcare provider utilization of EBM drives specialist selection, improved care quality, and cost

Senior Medical Director and Executive Director, Clinical Research National Senior Medical Director
Optum Care

Regional Medical Director, Florida
WellMed Medical Management

Chief Medical Officer
Surgical Care Associates President
OptumCare Specialty Practices

Chief Medical Officer
Reliant Medical Group

Success in Value Based Contracting – Using Evidence, Technology and Data to Improve Outcomes and Eliminate Low Value Care

Precision medicine is redefining how we evaluate and treat disease. No longer is cancer defined by its organ of origin, tissue or cell type but rather its genotype.

Conducting traditional 3-phased clinical trials in these orphan disease categories on a myriad of novel therapeutics, while trying to expedite therapies from lab bench to bedside is forcing a transformation of both the clinical development and regulatory process. From cohort expansion to accelerated pathways to decentralized trials, this transformation has placed real-world evidence at the center of the approval process.

We’ll explore how the traditional one-size-fits-all clinical development and regulatory approval paradigm has evolved to become an increasingly customizable process.

 on July 19, 2021, at 12:00 PM EDT for the latest Oncology Value Coalition webinar with Cardinal Health.

The evolution and complexity of FDA regulatory pathways,

The impact of the pandemic on decentralized trial design,

The role real-world evidence will likely play in the future of drug approvals

How all of this sets the stage for understanding Biogen’s approach to Aducanumab


Vice President of Clinical Affairs and Chief Medical Officer
Cardinal Health Specialty Solutions

Vice President and Chief Medical Officer
Cardinal Health Specialty Solutions


Director of Real-World Evidence & Insights
Cardinal Health Specialty Solutions


Director of Real-World Evidence and Regulatory Sciences
Cardinal Health Specialty Solutions